Stockscreener 앱 받기
2.71
2.87%
-0.08
전일 마감가:
$2.79
열려 있는:
$2.8
하루 거래량:
267.64K
Relative Volume:
1.03
시가총액:
$179.23M
수익:
-
순이익/손실:
$-71.17M
주가수익비율:
-1.7484
EPS:
-1.55
순현금흐름:
$-70.97M
1주 성능:
-20.99%
1개월 성능:
-48.67%
6개월 성능:
-42.34%
1년 성능:
-29.24%
1일 변동 폭
$2.63
$2.8037
1주일 범위
$2.63
$3.48
52주 변동 폭
$2.63
$7.795
이노즈메 Stock (INZY) Company Profile
명칭
Inozyme Pharma Inc
전화
857-330-4340
주소
321 SUMMER STREET, BOSTON
INZY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| INZY | 2.715 | 179.23M | 0 | -71.17M | -70.97M | -1.55 |
| VRTX | 450.01 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.02 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 594.70 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 245.85 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.66 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
이노즈메 Stock (INZY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-12 | 개시 | Stifel | Buy |
| 2024-08-13 | 재개 | Jefferies | Buy |
| 2024-05-30 | 개시 | Wells Fargo | Overweight |
| 2023-03-23 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-05-26 | 개시 | Jefferies | Hold |
| 2022-02-07 | 개시 | H.C. Wainwright | Buy |
| 2021-11-29 | 개시 | Needham | Buy |
| 2020-08-18 | 개시 | BofA Securities | Buy |
| 2020-08-18 | 개시 | Cowen | Outperform |
| 2020-08-18 | 개시 | Piper Sandler | Overweight |
| 2020-08-18 | 개시 | Wedbush | Outperform |
모두보기
이노즈메 주식(INZY)의 최신 뉴스
Inozyme Pharma, Inc. (NASDAQ:INZY) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Here's Why Inozyme Pharma (INZY) is Poised for a Turnaround After Losing -29.98% in 4 Weeks - MSN
Does Inozyme Pharma (NASDAQ:INZY) Have A Healthy Balance Sheet? - Simply Wall St
Inozyme Pharma stock hits 52-week low at $3.23 amid market shifts - Investing.com
Eventide Asset Management's Strategic Acquisition of Inozyme Pha - GuruFocus.com
Inozyme Pharma to Present at Upcoming Investor Conferences - GlobeNewswire
Inozyme Pharma CEO to Present at Stifel and Jefferies Healthcare Conferences | INZY Stock News - StockTitan
Inozyme Pharma’s (INZY) Buy Rating Reiterated at HC Wainwright - Defense World
Inozyme Pharma (NASDAQ:INZY) Given “Outperform” Rating at Wedbush - Defense World
FY2024 EPS Estimates for Inozyme Pharma Increased by Analyst - Defense World
Inozyme Pharma FY2024 EPS Forecast Raised by HC Wainwright - MarketBeat
FY2024 EPS Estimates for Inozyme Pharma Raised by Analyst - MarketBeat
Piper Sandler raises Inozyme Pharma target to $43 from $40 - Investing.com India
Inozyme Pharma's (INZY) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Inozyme Pharma's (INZY) Buy Rating Reaffirmed at Needham & Company LLC - MarketBeat
Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights - GlobeNewswire
Inozyme Pharma’s Q3 2024 Financial and Clinical Progress - TipRanks
Piper Sandler raises Inozyme Pharma target to $43 from $40 By Investing.com - Investing.com Canada
Inozyme Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Inozyme Pharma Reports Wider Q3 Loss, Advances Key Clinical Trials Despite $24.6M Loss | INZY Stock News - StockTitan
Analysts Set Inozyme Pharma, Inc. (NASDAQ:INZY) Price Target at $16.14 - MarketBeat
Inozyme Pharma, Inc. (NASDAQ:INZY) Receives Average Rating of “Buy” from Analysts - Defense World
Needham & Company LLC Reiterates Buy Rating for Inozyme Pharma (NASDAQ:INZY) - MarketBeat
Inozyme reports positive trial results for kidney disease therapy - Investing.com India
Inozyme reports positive trial results for kidney disease therapy By Investing.com - Investing.com Canada
Inozyme Pharma Bullish on Treatment for End-Stage Kidney Disease - MarketWatch
Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701 - GlobeNewswire
The Manufacturers Life Insurance Company Grows Position in Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
(INZY) Proactive Strategies - Stock Traders Daily
Inozyme Pharma presents kidney disease study at ASN Kidney Week By Investing.com - Investing.com Nigeria
Inozyme Pharma presents kidney disease study at ASN Kidney Week - Investing.com
Inozyme Pharma Announces Presentation of Interim Data from - GlobeNewswire
Short Interest in Inozyme Pharma, Inc. (NASDAQ:INZY) Decreases By 6.9% - MarketBeat
Dimensional Fund Advisors LP Purchases 205,417 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
Inozyme Pharma, Inc. (NASDAQ:INZY) Shares Bought by Dimensional Fund Advisors LP - MarketBeat
Millennium Management LLC Acquires 1,084,341 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY) - MarketBeat
Cubist Systematic Strategies LLC Invests $84,000 in Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
Inozyme Pharma appoints new board member - Investing.com
Inozyme Pharma appoints new board member By Investing.com - Investing.com South Africa
Inozyme Pharma Welcomes New Director Erik Harris - TipRanks
Inozyme appoints Erik Harris to board of directors - TipRanks
Inozyme Pharma Appoints Erik Harris to its Board of Directors - citybiz
Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its - The Bakersfield Californian
Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors - GlobeNewswire
Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of - EIN News
How the (INZY) price action is used to our Advantage - Stock Traders Daily
Inozyme Pharma, Inc. (NASDAQ:INZY) Shares Purchased by American Century Companies Inc. - Defense World
Inozyme Pharma, Inc. (NASDAQ:INZY) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Inozyme Pharma, Inc. (NASDAQ:INZY) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Wedbush Reiterates "Outperform" Rating for Inozyme Pharma (NASDAQ:INZY) - MarketBeat
이노즈메 (INZY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.80%
0.42%
자본화:
|
볼륨(24시간):